Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
2026 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Korea
Global pharma’s steady interest, a people-first health agenda, and a push for bolder M&A moves highlight Korea’s pivotal moment in biopharma. The nation’s policy shifts and deal-making trends could redefine its global standing.
New South Korea Health Minister Vows ‘People-Centric’ Medical System
In line with new President Lee’s campaign pledges, South Korea's newly confirmed health minister is expected to tackle key issues including a prolonged doctors' conflict, essential drug supplies and R&D support for the industry.
Korea Needs To Think Bigger On M&As: KHIDI
By Jung Won Shin and Kosh Naran
A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.